Mallinckrodt announces publication of two journal manuscripts with clinical and economic evidence for acthar® gel (repository corticotropin injection)

– clinical findings from historical manuscript published in clinical drug investigation reinforce the efficacy, safety profile, and use of acthar gel in appropriate patients across 12 autoimmune and inflammatory indications1 – – economic findings from manuscript published in clinicoeconomics and outcomes research support acthar gel's clinical and economic benefits for patients across nine autoimmune and inflammatory indications2 – dublin , oct. 10, 2023 /prnewswire/ -- mallinckrodt plc (otcmkts: mnktq), a global specialty pharmaceutical company, today announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of acthar gel for appropriate patients across a range of fda-approved autoimmune and inflammatory disease indications.1,2  mallinckrodt's clinical manuscript titled "acthar gel treatment for patients with autoimmune and inflammatory diseases: a historical perspective and characterization of clinical evidence" was published on october 4, 2023 in the journal, clinical drug investigation.  mallinckrodt's health economics manuscript titled "acthar gel (rci): a narrative literature review of clinical and economic evidence" was published on june 24, 2023 in clinicoeconomics and outcomes research.
MNK Ratings Summary
MNK Quant Ranking